Loading…
← CockpitCompetitor Analysis › LGND Ligand Pharmaceuticals IncorporatedOpen in the cockpit ↗

Ligand Pharmaceuticals IncorporatedLGNDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Royalty-based biopharma that licenses drug technologies (like Captisol) and collects royalties on partners' approved drugs.

Momentum leader 82
Mkt cap
$5.98B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$71.8M
20-day average traded
Fwd P/E
27.3×
forward earnings
ROIC−WACC
-8.4 pp
WACC 10.1%
Hurdle
+50 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$298.71
1D+1.7%
1W-5.7%
1M-2.5%
3M+3.9%
6M+37.2%
YTD+58.0%
1Y+48.4%
ATR %3.8%
Beta0.88
52w lowhigh8.6% off high

What Ligand Pharmaceuticals does

Royalty-based biopharma that licenses drug technologies (like Captisol) and collects royalties on partners' approved drugs.

Earns royalties on partners' drug sales, such as Amgen's Kyprolis, and sells Captisol, an ingredient that makes drugs dissolve, to drugmakers that use it in their products, plus milestone payments when partners hit trial or sales targets. Partners fund most development, so Ligand carries few such costs itself. It spun off its antibody platform, OmniAb, in 2022.

Products and services

  • Captisol formulation technology
  • Royalty portfolio on partnered drugs
  • OmniAb antibody-platform royalties

Customers

  • Biotech/pharma licensees
  • Investors

Where it sits in the supply chain

  • Pharmaceuticals
  • Biopharma royalty/licensing
  • Drug-technology licensing

What could go right

  • Growing royalty income as partner drugs launch/grow
  • Captisol demand tied to new formulated drugs

What could go wrong

  • Concentration risk in a few large royalty streams
  • Patent expiry on underlying licensed technology

Moat: narrow (IP / patents, scale). A broad portfolio of licensed technology and royalty stakes spreads risk across many partners' drugs.

Headquarters: San Diego, California, United States · Founded: 1987 · Employees: 47

Named competitors

Ligand Pharmaceuticals at a glance

Size Ligand Pharmaceuticals (LGND) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.98B, the 1061st largest of 3,085 United States companies the cockpit tracks. Shares closed at $298.71 on 18 Nov 2026.

Performance Over six months the shares gained 37.2%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 1.0% over the last twelve months (peer median +13.4%); the operating margin is 14.4% (peer median 19.4%).

Valuation It trades at 27.3× forward earnings against a peer median of 19.3× (6th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +50 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.4 points below its cost of capital (10.1% WACC).

Credit Ligand Pharmaceuticals has 2 bonds outstanding ($1.16B).

Short interest Short interest is 12.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026LGND 134Peer median 93
Six months, rebased to 100: Ligand Pharmaceuticals against the median of its 20 peers (local-currency closes).

Ligand Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$254M$268M$167M$131M$196M
Revenue growth—+60%+27%-33%—
Gross profit$207M$221M$121M$88.0M$119M
EBITDA$73.5M$80.9M$60.4M$47.2M$56.2M
Net income$51.5M$124M-$4.03M$52.2M-$33.4M
Free cash flow$90.6M$48.9M$94.8M$45.1M$120M
Capital expenditure$33.6M$11.3M$19.6M$53.8M$17.9M
Total debt$1.15B$451M$7.11M$6.17M$87.7M

Quarterly statements and history in the cockpit →

Ligand Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%0%+50%SUPNMIRM9995ABBOTINDIAGLANDBIOCON603087BLTE0126Z0ORKA000999ALKEM0009636885789926LQDABANBLGND6-month return →1-month return →
Up and to the right = strong over both horizons. Ligand Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×60×SUPN9995ABBOTINDIAGLANDBIOCON603087APTX000999ALKEM4506LQDALGNDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ligand Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%SUPN9995GLANDAPTX688578LQDALGNDGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ligand Pharmaceuticals is the large dot.

Ligand Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (LGND vs RPRX vs INVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ligand Pharmaceuticals LGND$5.98B+37%+1%14%27.3×57.7%
Royalty Pharma RPRX$39.4B+29%+11%66%11.5×10.8%
Innoviva INVA$1.31B-17%+12%38%9.5×-17.2%

How Ligand Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ligand Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureLGNDPeer medianRank in peer set
1-month return-2.5%+1.2%8th lowest of 21
6-month return+37.2%-4.6%3rd highest of 20
Distance from 52-week high-8.6%-21.9%4th highest of 21
Revenue growth (TTM)+1.0%+13.4%lowest of 17
Operating margin14.4%19.4%8th lowest of 18
Forward P/E27.3×19.3×6th most expensive of 16
Growth the price implies (Req g, 7 yrs)57.7%1.7%most demanding of 12
Growth delivered (Del g)+7.5%+13.3%4th lowest of 12
Hurdle (Req g minus delivered)+50.2 pp-9.2 ppmost demanding of 12
ROIC minus cost of capital-8.4 pp+1.9 pp6th lowest of 18
EV / EBITDA90.9×20.5×most expensive of 10
Net debt / EBITDA9.6×0.3×most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a

Ligand Pharmaceuticals bonds and credit

Ligand Pharmaceuticals has 2 bonds outstanding with $1.16B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Ligand Pharmaceuticals's main competitors?
Named competitors: Royalty Pharma (RPRX), PDL BioPharma (private or unlisted), XOMA Royalty (private or unlisted), Innoviva (INVA). The cockpit's measured peer set (industry) also includes Supernus Pharmaceuticals (SUPN), Mirum Pharmaceuticals (MIRM), RemeGen (9995.HK), Abbott India (ABBOTINDIA.NS), Gland Pharma (GLAND.NS), Biocon (BIOCON.NS).
Is Ligand Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 27.3× against a peer median of 19.3×, 6th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +50 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Ligand Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +37.2% against -4.6% for the median peer; over one year +48.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.